Trials / Completed
CompletedNCT01735630
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 350 (actual)
- Sponsor
- OPKO Health, Inc. · Industry
- Sex
- All
- Age
- 50 Years – 95 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to determine whether ELND005 is effective in treating symptoms of agitation and aggression in patients with Alzheimer's disease
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ELND005 | |
| DRUG | Placebo |
Timeline
- Start date
- 2012-11-01
- Primary completion
- 2015-05-01
- Completion
- 2015-05-01
- First posted
- 2012-11-28
- Last updated
- 2019-10-21
- Results posted
- 2016-08-15
Locations
70 sites across 4 countries: United States, Canada, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT01735630. Inclusion in this directory is not an endorsement.